Dyslipidemia

In a time when doctors are busier than ever and patients still want to feel a personal connection to their health care professionals, finding new ways to have that balance has become a field of study for now and the future.

From cardiologists to physical therapists to nurses there is a team approach needed to provide cardiac patients the care they need for treatment. Keeping that care going even after a cardiac event has passed has been a growing focus of the field in recent years.

It has become unnecessary for dermatologists to request monthly lab tests for patients administered standard doses of isotretinoin for the treatment of severe acne.

Study results suggest that gout itself and not hyperuricemia alone is associated with left ventricular diastolic dysfunction and left atrial volume enlargement.

Leptin (an adipocyte-secreted hormone) has been an object of observation since 1994. Its levels in the body are roughly proportional to an individual's amount of adipose tissue. It seems to regulate energy homeostasis, decrease energy intake, and increase energy expenditure. From its discovery, researchers hoped that its manipulation could be useful clinically.

Study results show PCSK9 inhibitor alirocumab reduces cholesterol by increasing the fractional clearance rate of IDL and LDL.

Gilead Sciences recently filed a New Drug Application with the US Food and Drug Administration for a single-tablet regimen to treat chronic infection of all forms of the hepatitis C virus.

Study results suggest that screening for metabolic syndrome among patients taking antipsychotic medications occurs far less frequently than recommended by the guidelines.

The evidence indicates resistant starches improve glucose metabolism beyond what would be expected from its reduced glycemic index.

As part of a multi-institutional effort, researchers in the fields of proteomics, lipidomics, and metabolomics will collaborate to discover more effective ways of predicting which patients with type 1 diabetes are at greater risk for developing kidney disease.

Researchers in Australia recently reported that the immune signaling protein NLRP1 plays a key role in metabolism by activating fat-burning processes when the body's energy intake is too high.

At the 2015 Cardiometabolic Health Congress, Christie M. Ballantyne, MD, moderated a panel discussion focusing on current cholesterol guidelines and several changes that may be coming soon.

Lipid resuscitation therapy was identified in 1998 as an effective treatment for local anesthetic systemic toxicity. Since then, researchers have developed a better understanding of the risk factors involved and the manner in which lipids work, using both dynamic scavenging and direct cardiotonic effects.

Elevated levels of triglycerides have been proven time and time again to be linked to cardiovascular disease. While it can be a challenging condition to control, it opens the door for treatments.

Positive hepatitis C infection may increase risk for liver damage as well as future heart problems, according to findings published in The Journal of Infectious Diseases.

There is a positive association of measures of pulmonary function with lipoprotein a [Lp(a)] in older adults who live in a community setting, according to a recent study.

A study published in Metabolic Syndrome and Related Disorders indicates that sodium glucose cotransporter-2 inhibitors (SGLT2 inhibitors, which affect both supply and demand pathways in the heart) may be the preferred treatment for diabetics with heart failure.

The Sanofi/Regeneron PCSK9 inhibitor alirocumab (Praluent)- approved in July in the US - lowered cholesterol in patients with familial hypercholesterolemia to levels "unreachable with statins" researchers said at the European Society of Cardiology meeting in London, UK.

Cardiovascular diseases (CVDs) cause more than 52% of all deaths in females, according to the World Health Organization (WHO), and myocardial infarction (MI) incidence is increasing in the younger population.

Cardiovascular disease is the most common comorbidity in patients with rheumatoid arthritis (RA) and the reason behind it may have finally been identified.

The US Food and Drug Administration on Friday approved the first cholesterol-lowering treatment in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.

Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) project, a 4-year Centers for Medicare and Medicaid Services-sponsored demonstration project, showed that a telemedicine intervention can improve glycemic, lipid, and blood pressure control.

Friday could be a big day for cardiologists. The FDA is due to rule July 24 on what could be the first available PCSK9 inhibitor, one of a new class of cholesterol-lowering agents meant to help patients who cannot get their LDL levels low enough with statins. New York City cardiologist David Vorchheimer, MD. talks about his hopes for the new drugs, and a few concerns

Tocilizumab treated rheumatoid arthritis patients are at an increased risk for major adverse cardiovascular events, according to a study published in Arthritis & Rheumatology.

Advanced lipid testing can be useful in predicting cardiac risk, but tests are often underutilized.

The medical world is eagerly awaiting the likely approval this summer of two new cholesterol-lowering drugs, known as PCSK9 inhibitors. But at a cost of $7,000 to $12,000 a year, they won't be for everyone.

Lipid management is a complex issue. Peter Jones, MD, a Houston, TX, internist who specializes in lipidology, offers advice to primary care physicians trying to sort out competing treatment guidelines.

Dietary trans fatty acids have had their heyday and are fading from the American food landscape. Once ubiquitous in margarine, snack food, packaged baked goods, and fried fast food, they have been associated with adverse effects on lipid profiles, metabolic function, insulin resistance, inflammation, and cardiac and general health.

In previous studies, regular breakfast consumption has been correlated with lower BMI and improved cardiometabolic risk profile. Furthermore, evidence suggests that low-energy density, high-fiber, and high-carbohydrate foods may be more satiating when compared to their alternatives.

Analysis of a large patient cohort indicates a strong association between self-reported stress levels and atrial fibrillation.